Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Moderna, Inc. (MRNA)
USD67.01
-1.26 (-1.85%)
US NASDAQ S&P 500
NASDAQ 100
Healthcare Biotechnology
Address
325 Binney Street 2142
Cambridge, MA, US
Cambridge, MA, US
CEO
Stéphane Bancel
Website
modernatx.com
IPO
2018-12-07
CIK 1682852 ISIN US60770K1079
Also trades on
Frankfurt Stock Exchange · 0QF.F (EUR)
NASDAQ Global Select · MRNA (USD)
Description
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
News Sentiment (7d)
4 articles
- Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout 24/7 Wall Street
- Arbutus Biopharma: Moderna Validates My IP Bull Case Seeking Alpha
- Moderna wins EU contract for RSV vaccine supply Reuters
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026 Accesswire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 2021-07-20 | — | Active |
| NASDAQ 100 | 2020-07-20 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD67.01
-1.26 (-1.85%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
1.03
Float Shares
370.15M
Free Float %
93.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.74% | +3.06% | +4.53% | +32.81% | +99.44% | +80.64% | +107.28% | -58.80% | -65.11% | +186.40% | +186.40% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (27 ratings, all time)
Hold
Price Targets & DCF
Current price
67.01
Low
17.00
-74.6%
Consensus
39.00
-41.8%
Median
37.50
-44.0%
High
63.00
-6.0%
Ratings Trend (MoM)
17% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 16 | -2 |
| Sell | 1 | 0 |
| Strong Sell | 2 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 4 |
41.25
-38.4%
|
| Last Quarter | 10 |
37.80
-43.6%
|
| Last Year | 24 |
33.58
-49.9%
|
| All Time | 82 |
118.37
+76.6%
|
Quality scores
Altman Z-Score
3.49
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-39.2% Q1'26: +263.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+21.7% Q1'26: -34.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-130.9% Q1'26: -177.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-142.4% Q1'26: -356.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-58.1% Q1'26: -158.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.3% ★ Q1'26: +2.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.75× Q1'26: -0.24× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 15 Rev. Ana. 15 EPS Ana. |
Dec 2027 16 Rev. Ana. 15 EPS Ana. |
Dec 2028 17 Rev. Ana. 15 EPS Ana. |
Dec 2029 14 Rev. Ana. 10 EPS Ana. |
Dec 2030 8 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
135.07M
est: 124.18M (+8.8%)
|
60.21M
est: 75.42M (-20.2%)
|
803.40M
est: 534.89M (+50.2%)
|
17.74B
est: 18.02B (-1.6%)
|
18.88B
est: 19.13B (-1.3%)
|
6.85B
est: 5.05B (+35.6%)
|
3.20B
est: 3.21B (-0.3%)
|
1.94B
est: 1.91B (+1.9%)
|
2.09B
1.97B – 2.13B
+9.3% YoY
|
2.50B
1.87B – 4.38B
+19.8% YoY
|
3.17B
3.15B – 3.19B
+26.8% YoY
|
5.11B
4.27B – 7.57B
+61.1% YoY
|
6.83B
5.71B – 10.12B
+33.7% YoY
|
| EBITDA |
-412.05M
est: -26.69M (-1,443.9%)
|
-477.08M
est: -501.30M (+4.8%)
|
-703.38M
est: -570.48M (-23.3%)
|
13.53B
est: 12.80B (+5.7%)
|
9.77B
est: 14.95B (-34.7%)
|
-3.28B
est: -1.21B (-171.1%)
|
-3.39B
est: -769.45M (-341.1%)
|
-2.55B
est: -457.62M (-457.9%)
|
-500.14M
-509.90M – -473.31M
-9.3% YoY
|
-599.41M
-1.05B – -449.56M
-19.8% YoY
|
-760.20M
-765.44M – -754.96M
-26.8% YoY
|
-1.22B
-1.82B – -1.02B
-61.1% YoY
|
-1.64B
-2.43B – -1.37B
-33.7% YoY
|
| EBIT |
-436.91M
est: -30.69M (-1,323.6%)
|
-508.10M
est: -573.40M (+11.4%)
|
-734.63M
est: -623.20M (-17.9%)
|
13.30B
est: 12.57B (+5.8%)
|
9.42B
est: 14.60B (-35.5%)
|
-3.90B
est: -1.33B (-192.5%)
|
-3.58B
est: -847.86M (-322.6%)
|
-2.77B
est: -504.26M (-448.9%)
|
-551.11M
-561.86M – -521.54M
-9.3% YoY
|
-660.50M
-1.16B – -495.37M
-19.8% YoY
|
-837.67M
-843.45M – -831.89M
-26.8% YoY
|
-1.35B
-2.00B – -1.13B
-61.1% YoY
|
-1.80B
-2.68B – -1.51B
-33.7% YoY
|
| Net Income |
-384.73M
est: -590.08M (+34.8%)
|
-514.02M
est: -540.34M (+4.9%)
|
-747.06M
est: -607.66M (-22.9%)
|
12.20B
est: 11.55B (+5.7%)
|
8.36B
est: 13.15B (-36.4%)
|
-4.71B
est: -5.87B (+19.7%)
|
-3.56B
est: -2.90B (-22.7%)
|
-2.82B
est: -3.19B (+11.6%)
|
-3.41B
-3.93B – -2.60B
-6.7% YoY
|
-1.84B
-2.43B – -33.78M
+46.1% YoY
|
-1.15B
-2.41B – 269.48M
+37.5% YoY
|
-10.26M
-16.71M – -8.08M
+99.1% YoY
|
1.04B
816.60M – 1.69B
+10,202.2% YoY
|
| SGA |
94.25M
est: 22.84M (+312.7%)
|
109.62M
est: 13.87M (+690.3%)
|
188.27M
est: 155.31M (+21.2%)
|
567.00M
est: 538.85M (+5.2%)
|
1.13B
est: 777.62M (+45.6%)
|
1.55B
est: 1.22B (+26.9%)
|
1.17B
est: 775.63M (+51.4%)
|
1.02B
est: 461.30M (+120.7%)
|
504.16M
477.11M – 514.00M
+9.3% YoY
|
604.23M
453.17M – 1.06B
+19.8% YoY
|
766.31M
761.02M – 771.59M
+26.8% YoY
|
1.23B
1.03B – 1.83B
+61.1% YoY
|
1.65B
1.38B – 2.45B
+33.7% YoY
|
| EPS |
-1.17
est: -1.54 (+23.9%)
|
-1.55
est: -1.61 (+3.7%)
|
-1.96
est: -1.57 (-25.0%)
|
30.31
est: 27.27 (+11.2%)
|
21.26
est: 21.26 (+0.0%)
|
-12.34
est: -15.36 (+19.7%)
|
-9.27
est: -9.05 (-2.4%)
|
-7.26
est: -7.84 (+7.4%)
|
-8.51
-10.10 – -6.69
-8.6% YoY
|
-4.73
-6.25 – -0.09
+44.4% YoY
|
-2.87
-6.19 – 0.69
+39.4% YoY
|
-0.03
-0.04 – -0.02
+99.1% YoY
|
2.67
2.10 – 4.34
+10,202.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | UBS | Neutral | Neutral | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.82B
OE per share TTM
-4.67
Owner's Yield
-8.69%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
25.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
238
Total invested
523.38M
Insider transactions (90d)
0
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford & Co (Scottish partnership) | 45.77M | 11.00% | — | — | — | — | IA | SCOTLAND UK | 2022-01-26 | ↗ |
| 2 | shares of Common Stock held by a trust for the benefit of Mr. Bancel’s family, which has an independ | 31.60M | 12.00% | 31.60M | — | 31.60M | — | IN | France | 2020-02-13 | ↗ |
| 3 | 7.64% (2) | 31.54M | 7.64% | 31.54M | — | 31.54M | — | IN | France | 2022-02-14 | ↗ |
| 4 | 9.3%(2) | 31.14M | 9.30% | 31.14M | — | — | — | IN | Delaware | 2019-02-14 | ↗ |
| 5 | (1) BlackRock, Inc. | 27.66M | 6.80% | 24.97M | — | 27.66M | — | HC | Delaware | 2022-02-04 | ↗ |
| 6 | The Vanguard Group - 23-1945930 | 27.43M | 6.76% | — | 595.8K | 25.98M | 1.45M | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 7 | Ph.D. | 20.01M | 4.90% | 2.39M | 17.61M | 2.39M | 17.61M | IN | — | 2022-02-14 | ↗ |
| 8 | Fund IV General Partner LLC | 17.58M | 4.30% | — | 17.58M | — | 17.58M | OO | — | 2022-02-14 | ↗ |
| 9 | David C. Ott | 17.10M | 5.20% | — | 17.10M | — | — | IN | United States | 2018-12-21 | ↗ |
| 10 | O. Andreas Halvorsen | 17.10M | 5.20% | — | 17.10M | — | — | IN | Norway | 2018-12-21 | ↗ |
| 11 | Rose S. Shabet | 17.10M | 5.20% | — | 17.10M | — | — | IN | United States | 2018-12-21 | ↗ |
| 12 | Viking Global Investors LP | 17.10M | 5.20% | — | 17.10M | — | — | PN | Delaware | 2018-12-21 | ↗ |
| 13 | Fund IV, LP | 14.74M | 3.60% | — | 14.74M | — | 14.74M | PN | — | 2022-02-14 | ↗ |
| 14 | VentureLabs IV, LLC | 11.46M | 2.80% | — | 11.46M | — | 11.46M | OO | — | 2022-02-14 | ↗ |
| 15 | Viking Global Performance LLC | 10.20M | 3.10% | — | 10.20M | — | — | OO | Delaware | 2018-12-21 | ↗ |
| 16 | 10. | 9.25M | 2.80% | 9.25M | — | — | — | OO | Delaware | 2019-02-14 | ↗ |
| 17 | VGE III Portfolio Ltd. | 6.52M | 2.00% | — | 6.52M | — | — | CO | Cayman Islands | 2018-12-21 | ↗ |
| 18 | Viking Long Fund GP LLC | 4.18M | 1.30% | — | 4.18M | — | — | OO | Delaware | 2018-12-21 | ↗ |
| 19 | Viking Long Fund Master Ltd. | 4.18M | 1.30% | — | 4.18M | — | — | CO | Cayman Islands | 2018-12-21 | ↗ |
| 20 | Viking Global Equities LP | 3.48M | 1.10% | — | 3.48M | — | — | PN | Delaware | 2018-12-21 | ↗ |
| 21 | IV-Rx, | 2.84M | 0.70% | — | 2.84M | — | 2.84M | PN | — | 2022-02-14 | ↗ |
| 22 | Viking Global Opportunities GP LLC | 2.71M | 0.80% | — | 2.71M | — | — | OO | Delaware | 2018-12-21 | ↗ |
| 23 | Viking Global Opportunities Portfolio GP LLC | 2.71M | 0.80% | — | 2.71M | — | — | OO | Delaware | 2018-12-21 | ↗ |
| 24 | Viking Global Opportunities Illiquid Investments Sub-Master LP | 2.67M | 0.80% | — | 2.67M | — | — | PN | Cayman Islands | 2018-12-21 | ↗ |
| 25 | Viking Global Equities II LP | 204.0K | 0.06% | — | 204.0K | — | — | PN | Delaware | 2018-12-21 | ↗ |
| 26 | Viking Global Opportunities Liquid Portfolio Sub-Master LP | 41.6K | 0.01% | — | 41.6K | — | — | PN | Cayman Islands | 2018-12-21 | ↗ |
| 27 | Pioneering, Inc. | 37.0K | 0.10% | 37.0K | — | 37.0K | — | CO | — | 2022-02-14 | ↗ |
| 28 | AstraZeneca PLC | — | 0.00% | — | — | — | — | CO | United Kingdom | 2021-02-10 | ↗ |
| 29 | Zeneca Inc. | — | 0.00% | — | — | — | — | CO | Delaware | 2021-02-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
238
-505 vs prev Q
New positions
48
Closed positions
498
Increased
122
Reduced
48
Put/Call ratio
6.89
Calls held
23.3K
Puts held
160.3K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 645.0K +645.0K (+100.0%) | 19.02B +19.0B (+100.0%) | 0.17% +0.165 pp | 8.71% +8.712 pp | USD29.49 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 41.58M +399.5K (+1.0%) | 1.23B +162.5M (+15.3%) | 10.61% -0.006 pp | 0.02% +0.002 pp | USD118.56 -75.1% | 29 qtrs — |
| 3 | BLACKROCK, INC. | 32.51M +3.0M (+10.1%) | 958.59M +195.9M (+25.7%) | 8.29% +0.682 pp | 0.02% +0.003 pp | USD58.29 -49.4% | 6 qtrs — |
| 4 | FMR LLC | 28.05M +15.7M (+127.9%) | 827.06M +509.2M (+160.2%) | 7.15% +3.983 pp | 0.04% +0.026 pp | USD59.86 -50.7% | 29 qtrs — |
| 5 | BAILLIE GIFFORD & CO | 20.58M -1.3M (-5.8%) | 606.92M +42.6M (+7.6%) | 5.28% -0.354 pp | 0.50% +0.086 pp | USD121.13 -75.7% | 29 qtrs — |
| 6 | STATE STREET CORP | 16.37M -743.1K (-4.3%) | 482.62M +40.7M (+9.2%) | 4.17% -0.235 pp | 0.02% +0.001 pp | USD185.20 -84.1% | 28 qtrs — |
| 7 | CAPITAL WORLD INVESTORS | 12.83M +12.8M (+100.0%) | 378.30M +378.3M (+100.0%) | 3.29% +3.289 pp | 0.05% +0.051 pp | USD29.49 +0.0% | 1 qtrs NEW |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 9.22M -29.7K (-0.3%) | 271.42M +32.9M (+13.8%) | 2.35% -0.032 pp | 0.02% +0.002 pp | USD140.33 -79.0% | 29 qtrs — |
| 9 | MORGAN STANLEY | 8.87M -1.1M (-11.0%) | 261.60M +4.3M (+1.7%) | 2.26% -0.305 pp | 0.02% +0.000 pp | USD55.98 -47.3% | 29 qtrs — |
| 10 | THELEME PARTNERS LLP | 8.08M +13.0K (+0.2%) | 238.33M +29.9M (+14.4%) | 2.06% -0.018 pp | 15.52% +2.194 pp | USD95.21 -69.0% | 29 qtrs — |
| 11 | TWO SIGMA ADVISERS, LP | 7.73M +956.8K (+14.1%) | 227.95M +53.0M (+30.3%) | 1.97% +0.226 pp | 0.44% +0.093 pp | USD28.60 +3.1% | 11 qtrs — |
| 12 | TWO SIGMA INVESTMENTS, LP | 7.34M -187.9K (-2.5%) | 216.52M +22.0M (+11.3%) | 1.87% -0.068 pp | 0.31% +0.016 pp | USD31.26 -5.7% | 12 qtrs — |
| 13 | INVESCO LTD. | 7.03M -1.2M (-14.4%) | 207.31M -4.9M (-2.3%) | 1.79% -0.324 pp | 0.03% -0.002 pp | USD81.63 -63.9% | 28 qtrs — |
| 14 | CITADEL ADVISORS LLC | 6.90M +463.6K (+7.2%) | 203.38M +37.2M (+22.4%) | 1.76% +0.101 pp | 0.03% +0.005 pp | USD70.26 -58.0% | 28 qtrs — |
| 15 | FLAGSHIP PIONEERING INC. | 4.63M +— (+0.0%) | 136.60M +17.0M (+14.2%) | 1.18% -0.012 pp | 42.16% +1.268 pp | USD15.27 +93.1% | 29 qtrs — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 4.62M +309.1K (+7.2%) | 136.29M +24.9M (+22.4%) | 1.18% +0.068 pp | 0.02% +0.003 pp | USD98.97 -70.2% | 26 qtrs — |
| 17 | BNP PARIBAS ARBITRAGE, SNC | 4.15M +3.1M (+279.7%) | 122.46M +94.2M (+333.5%) | 1.06% +0.778 pp | 0.06% +0.040 pp | USD49.82 -40.8% | 27 qtrs — |
| 18 | UBS GROUP AG | 4.09M -714.8K (-14.9%) | 120.52M -3.5M (-2.8%) | 1.04% -0.195 pp | 0.02% +0.000 pp | USD55.00 -46.4% | 29 qtrs — |
| 19 | GOLDMAN SACHS GROUP INC | 3.95M +770.9K (+24.2%) | 116.50M +34.4M (+41.8%) | 1.01% +0.194 pp | 0.01% +0.004 pp | USD113.16 -73.9% | 29 qtrs — |
| 20 | TOROSO INVESTMENTS, LLC | 3.91M -4.1M (-50.9%) | 115.36M -90.5M (-44.0%) | 1.00% -1.056 pp | 0.27% -0.138 pp | USD25.93 +13.7% | 9 qtrs — |
| 21 | ALYESKA INVESTMENT GROUP, L.P. | 3.23M +3.2M (+100.0%) | 95.21M +95.2M (+100.0%) | 0.82% +0.824 pp | 0.27% +0.269 pp | USD29.49 +0.0% | 1 qtrs NEW |
| 22 | JANE STREET GROUP, LLC | 3.21M +614.9K (+23.7%) | 94.54M +27.6M (+41.3%) | 0.82% +0.154 pp | 0.01% +0.004 pp | USD32.39 -9.0% | 6 qtrs — |
| 23 | BANQUE PICTET & CIE SA | 3.13M +— (+0.0%) | 92.33M +11.5M (+14.2%) | 0.80% -0.004 pp | 0.54% +0.071 pp | USD23.58 +25.1% | 27 qtrs — |
| 24 | NORTHERN TRUST CORP | 3.00M +97.1K (+3.3%) | 88.55M +13.5M (+18.0%) | 0.77% +0.017 pp | 0.01% +0.002 pp | USD163.30 -81.9% | 28 qtrs — |
| 25 | NORGES BANK | 2.70M +2.7M (+100.0%) | 79.71M +79.7M (+100.0%) | 0.69% +0.693 pp | 0.01% +0.009 pp | USD29.49 +0.0% | 1 qtrs NEW |
| 26 | SQUAREPOINT OPS LLC | 2.61M -1.9M (-42.5%) | 76.95M -40.3M (-34.4%) | 0.67% -0.505 pp | 0.08% -0.036 pp | USD31.46 -6.3% | 20 qtrs — |
| 27 | MERCK & CO., INC. | 2.31M +— (+0.0%) | 68.07M +8.4M (+14.2%) | 0.59% -0.006 pp | 24.64% -1.508 pp | USD41.58 -29.1% | 5 qtrs — |
| 28 | FEDERATED HERMES, INC. | 2.18M -600.5K (-21.6%) | 64.25M -7.5M (-10.5%) | 0.56% -0.158 pp | 0.11% -0.019 pp | USD27.77 +6.2% | 25 qtrs — |
| 29 | NATIONAL BANK OF CANADA /FI/ | 2.16M -548.6K (-20.3%) | 63.59M -6.3M (-9.0%) | 0.55% -0.147 pp | 0.06% -0.012 pp | USD28.69 +2.8% | 17 qtrs — |
| 30 | CITIGROUP INC | 1.94M -145.5K (-7.0%) | 57.11M +3.3M (+6.2%) | 0.49% -0.043 pp | 0.03% +0.001 pp | USD65.95 -55.3% | 28 qtrs — |
| 31 | D. E. SHAW & CO., INC. | 1.87M +490.1K (+35.6%) | 55.05M +19.5M (+54.8%) | 0.48% +0.121 pp | 0.03% +0.010 pp | USD40.61 -27.4% | 23 qtrs — |
| 32 | QUBE RESEARCH & TECHNOLOGIES LTD | 1.81M +230.4K (+14.6%) | 53.40M +12.6M (+30.8%) | 0.46% +0.055 pp | 0.05% +0.012 pp | USD39.22 -24.8% | 10 qtrs — |
| 33 | DIMENSIONAL FUND ADVISORS LP | 1.79M +987.3K (+123.2%) | 52.78M +32.1M (+155.0%) | 0.46% +0.252 pp | 0.01% +0.007 pp | USD82.72 -64.3% | 26 qtrs — |
| 34 | BANK OF NEW YORK MELLON CORP | 1.73M -33.4K (-1.9%) | 51.00M +5.5M (+12.0%) | 0.44% -0.011 pp | 0.01% +0.000 pp | USD195.83 -84.9% | 28 qtrs — |
| 35 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.62M -343.3K (-17.5%) | 47.64M -3.0M (-5.8%) | 0.41% -0.093 pp | 0.01% 0.000 pp | USD43.31 -31.9% | 29 qtrs — |
| 36 | UBS ASSET MANAGEMENT AMERICAS INC | 1.59M -371.8K (-19.0%) | 46.86M -3.8M (-7.5%) | 0.41% -0.098 pp | 0.01% -0.001 pp | USD114.16 -74.2% | 26 qtrs — |
| 37 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.55M +584.3K (+60.3%) | 45.82M +20.8M (+83.0%) | 0.40% +0.147 pp | 0.16% +0.077 pp | USD37.80 -22.0% | 6 qtrs — |
| 38 | BARCLAYS PLC | 1.54M +9.6K (+0.6%) | 45.49M -57.0M (-55.6%) | 0.39% -0.002 pp | 0.01% -0.015 pp | USD95.70 -69.2% | 28 qtrs — |
| 39 | FIRST TRUST ADVISORS LP | 1.50M +469.1K (+45.4%) | 44.28M +17.6M (+66.0%) | 0.38% +0.117 pp | 0.03% +0.012 pp | USD60.65 -51.4% | 24 qtrs — |
| 40 | BANK OF AMERICA CORP /DE/ | 1.37M -272.2K (-16.5%) | 40.54M -2.0M (-4.7%) | 0.35% -0.074 pp | 0.00% +0.000 pp | USD69.85 -57.8% | 29 qtrs — |
| 41 | DOUGLAS LANE & ASSOCIATES, LLC | 1.29M +163.0K (+14.4%) | 38.09M +8.9M (+30.7%) | 0.33% +0.040 pp | 0.52% +0.114 pp | USD67.88 -56.6% | 19 qtrs — |
| 42 | ROYAL BANK OF CANADA | 1.14M -513.8K (-31.0%) | 33.73M -9.1M (-21.2%) | 0.29% -0.135 pp | 0.01% -0.002 pp | USD55.70 -47.1% | 29 qtrs — |
| 43 | AMUNDI | 1.14M +127.6K (+12.6%) | 33.73M +5.7M (+20.5%) | 0.29% +0.030 pp | 0.01% +0.000 pp | USD77.87 -62.1% | 19 qtrs — |
| 44 | NUVEEN, LLC | 1.12M +22.5K (+2.0%) | 33.17M +4.7M (+16.5%) | 0.29% +0.003 pp | 0.01% +0.001 pp | USD27.84 +5.9% | 4 qtrs — |
| 45 | DEUTSCHE BANK AG\ | 1.12M -142.8K (-11.3%) | 33.03M +411.1K (+1.3%) | 0.29% -0.038 pp | 0.01% 0.000 pp | USD100.90 -70.8% | 28 qtrs — |
| 46 | JPMORGAN CHASE & CO | 1.01M -373.2K (-26.9%) | 29.90M -5.9M (-16.5%) | 0.26% -0.098 pp | 0.00% 0.000 pp | USD45.80 -35.6% | 29 qtrs — |
| 47 | WHITEFORT CAPITAL MANAGEMENT, LP | 1.00M +1.0M (+100.0%) | 29.49M +29.5M (+100.0%) | 0.26% +0.255 pp | 7.54% +7.539 pp | USD29.49 +0.0% | 1 qtrs NEW |
| 48 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1.00M +— (+0.0%) | 29.49M +3.7M (+14.2%) | 0.26% -0.003 pp | 0.38% -0.018 pp | USD25.83 +14.2% | 2 qtrs — |
| 49 | NATIXIS | 1.00M -600.0K (-37.5%) | 29.49M -11.8M (-28.6%) | 0.26% -0.157 pp | 0.10% -0.087 pp | USD26.49 +11.3% | 3 qtrs — |
| 50 | LEGAL & GENERAL GROUP PLC | 937.0K -64.3K (-6.4%) | 27.63M +1.8M (+6.8%) | 0.24% -0.018 pp | 0.01% +0.000 pp | USD127.65 -76.9% | 29 qtrs — |
| 51 | PICTET ASSET MANAGEMENT HOLDING SA | 738.1K +3.6K (+0.5%) | 22.87M +4.2M (+22.7%) | 0.19% +0.000 pp | 0.02% +0.004 pp | USD61.41 -52.0% | 10 qtrs — |
| 52 | SESSA CAPITAL IM, L.P. | 743.1K +— (+0.0%) | 21.91M +2.7M (+14.2%) | 0.19% -0.002 pp | 0.41% -0.045 pp | USD28.35 +4.0% | 4 qtrs — |
| 53 | LETKO, BROSSEAU & ASSOCIATES INC | 726.4K -187.0K (-20.5%) | 21.42M -2.2M (-9.2%) | 0.19% -0.049 pp | 0.35% -0.055 pp | USD65.78 -55.2% | 9 qtrs — |
| 54 | LMR PARTNERS LLP | 699.3K +108.7K (+18.4%) | 20.62M +5.4M (+35.2%) | 0.18% +0.026 pp | 0.04% -0.029 pp | USD30.22 -2.4% | 11 qtrs — |
| 55 | SWISS NATIONAL BANK | 693.1K +18.2K (+2.7%) | 20.44M +3.0M (+17.2%) | 0.18% +0.004 pp | 0.01% +0.002 pp | USD106.97 -72.4% | 23 qtrs — |
| 56 | TANG CAPITAL MANAGEMENT LLC | 692.8K +387.5K (+126.9%) | 20.43M +12.5M (+159.1%) | 0.18% +0.098 pp | 1.01% +0.706 pp | USD34.72 -15.1% | 5 qtrs — |
| 57 | CAPTION MANAGEMENT, LLC | 644.3K +477.3K (+285.8%) | 19.00M +14.7M (+340.5%) | 0.16% +0.121 pp | 0.13% +0.097 pp | USD28.54 +3.3% | 2 qtrs — |
| 58 | HSBC HOLDINGS PLC | 638.4K -107.1K (-14.4%) | 18.91M +717.0 (+0.0%) | 0.16% -0.028 pp | 0.01% -0.001 pp | USD133.81 -78.0% | 24 qtrs — |
| 59 | JUMP FINANCIAL, LLC | 625.9K +127.4K (+25.6%) | 18.46M +5.6M (+43.4%) | 0.16% +0.031 pp | 0.23% +0.073 pp | USD26.71 +10.4% | 10 qtrs — |
| 60 | RHUMBLINE ADVISERS | 620.7K -41.4K (-6.3%) | 18.30M +1.2M (+7.0%) | 0.16% -0.012 pp | 0.01% +0.001 pp | USD131.49 -77.6% | 28 qtrs — |
| 61 | RENAISSANCE TECHNOLOGIES LLC | 568.4K +568.4K (+100.0%) | 16.76M +16.8M (+100.0%) | 0.15% +0.145 pp | 0.03% +0.026 pp | USD29.49 +0.0% | 8 qtrs — |
| 62 | AQUATIC CAPITAL MANAGEMENT LLC | 549.7K +508.6K (+1,238.9%) | 16.21M +15.1M (+1,428.7%) | 0.14% +0.130 pp | 0.46% +0.441 pp | USD29.22 +0.9% | 2 qtrs — |
| 63 | CAPITAL FUND MANAGEMENT S.A. | 546.6K -244.9K (-30.9%) | 16.12M -4.3M (-21.2%) | 0.14% -0.065 pp | 0.04% -0.009 pp | USD47.06 -37.3% | 20 qtrs — |
| 64 | PEAK6 LLC | 543.5K +24.5K (+4.7%) | 16.03M +2.6M (+19.6%) | 0.14% +0.006 pp | 0.03% +0.010 pp | USD34.07 -13.4% | 5 qtrs — |
| 65 | MAN GROUP PLC | 518.3K -673.5K (-56.5%) | 15.28M -15.5M (-50.4%) | 0.13% -0.175 pp | 0.03% -0.028 pp | USD26.09 +13.0% | 25 qtrs — |
| 66 | EXOR CAPITAL LLP | 498.7K +125.6K (+33.7%) | 14.71M +5.1M (+52.6%) | 0.13% +0.032 pp | 0.26% +0.078 pp | USD88.43 -66.7% | 11 qtrs — |
| 67 | PRICE T ROWE ASSOCIATES INC /MD/ | 494.0K +11.1K (+2.3%) | 14.57M +2.1M (+16.8%) | 0.13% +0.002 pp | 0.00% +0.000 pp | USD114.76 -74.3% | 29 qtrs — |
| 68 | TUDOR INVESTMENT CORP ET AL | 485.0K -422.8K (-46.6%) | 14.30M -9.1M (-39.0%) | 0.12% -0.110 pp | 0.03% -0.014 pp | USD41.71 -29.3% | 10 qtrs — |
| 69 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 479.0K +13.1K (+2.8%) | 14.12M +2.1M (+17.4%) | 0.12% +0.003 pp | 0.01% +0.001 pp | USD72.44 -59.3% | 26 qtrs — |
| 70 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 471.0K +471.0K (+100.0%) | 13.89M +13.9M (+100.0%) | 0.12% +0.120 pp | 0.21% +0.214 pp | USD29.49 +0.0% | 3 qtrs — |
| 71 | Y-INTERCEPT (HONG KONG) LTD | 460.9K +460.9K (+100.0%) | 13.59M +13.6M (+100.0%) | 0.12% +0.118 pp | 0.30% +0.304 pp | USD29.49 +0.0% | 7 qtrs — |
| 72 | VOYA INVESTMENT MANAGEMENT LLC | 456.4K +343.6K (+304.5%) | 13.46M +10.5M (+361.8%) | 0.12% +0.088 pp | 0.01% +0.010 pp | USD49.34 -40.2% | 26 qtrs — |
| 73 | VERITION FUND MANAGEMENT LLC | 452.5K +230.2K (+103.5%) | 13.35M +7.6M (+132.4%) | 0.12% +0.058 pp | 0.05% +0.029 pp | USD35.39 -16.7% | 9 qtrs — |
| 74 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 447.7K -8.3K (-1.8%) | 13.20M +1.4M (+12.1%) | 0.11% -0.003 pp | 0.01% +0.001 pp | USD122.06 -75.8% | 29 qtrs — |
| 75 | WALLEYE TRADING LLC | 445.5K -31.7K (-6.6%) | 13.14M +811.7K (+6.6%) | 0.11% -0.009 pp | 0.02% +0.000 pp | USD53.70 -45.1% | 27 qtrs — |
| 76 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 390.0K -24.2K (-5.8%) | 12.04M +1.3M (+12.5%) | 0.10% -0.007 pp | 0.01% +0.001 pp | USD146.18 -79.8% | 25 qtrs — |
| 77 | ALLIANCEBERNSTEIN L.P. | 405.2K -9.5K (-2.3%) | 11.95M +1.2M (+11.6%) | 0.10% -0.004 pp | 0.00% +0.000 pp | USD189.92 -84.5% | 28 qtrs — |
| 78 | CWM, LLC | 389.3K -1.0K (-0.3%) | 11.48M +1.4M (+13.9%) | 0.10% -0.001 pp | 0.03% +0.001 pp | USD60.60 -51.3% | 17 qtrs — |
| 79 | MILLENNIUM MANAGEMENT LLC | 388.5K -178.6K (-31.5%) | 11.46M -3.2M (-21.8%) | 0.10% -0.047 pp | 0.00% -0.001 pp | USD82.62 -64.3% | 22 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.76
Neutral
Ratio by volume
2.01
Bullish
Buys
28
Sells
37
Shares acquired
977.9K
Shares disposed
485.7K
Cash buys
—
Cash sales
2.00
Net activity
+492,153
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | Mock James M | Officer | M-Exempt | A | Common Stock | 1,453 | 0.00 | — | 58,451 | D | ↗ |
| 2026-03-05 | Mock James M | Officer | M-Exempt | D | Restricted Stock Units | 11,797 | 0.00 | — | 129,774 | D | ↗ |
| 2026-03-05 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 11,797 | 0.00 | — | 129,774 | D | ↗ |
| 2026-03-02 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 13,885 | 52.29 | 726.0K | 59,689 | D | ↗ |
| 2026-03-01 | Mock James M | Officer | A-Award | A | Stock Option (Right to Buy) | 37,639 | 53.57 | 2.02M | 37,639 | D | ↗ |
| 2026-03-01 | Klinger Shannon Thyme | Officer | A-Award | A | Restricted Stock Units | 38,553 | 0.00 | — | 38,553 | D | ↗ |
| 2026-03-01 | Hoge Stephen | Officer | A-Award | A | Restricted Stock Units | 165,230 | 0.00 | — | 165,230 | D | ↗ |
| 2026-03-01 | Bancel Stephane | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 250,932 | 53.57 | 13.44M | 250,932 | D | ↗ |
| 2026-02-27 | Mock James M | Officer | M-Exempt | A | Common Stock | 9,901 | 0.00 | — | 55,693 | D | ↗ |
| 2026-02-27 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 774 | 0.00 | — | 6,189 | D | ↗ |
| 2026-02-27 | Hoge Stephen | Officer | M-Exempt | A | Common Stock | 37,131 | 0.00 | — | 1,495,950 | D | ↗ |
| 2026-02-23 | Hoge Stephen | Officer | M-Exempt | D | Stock Option (Right to Buy) | 48,330 | 19.15 | 925.5K | 48,330 | D | ↗ |
| 2026-02-11 | Mock James M | Officer | A-Award | A | Common Stock | 2,630 | 0.00 | — | 46,502 | D | ↗ |
| 2026-02-11 | Klinger Shannon Thyme | Officer | A-Award | A | Common Stock | 2,630 | 0.00 | — | 55,861 | D | ↗ |
| 2026-02-11 | Hoge Stephen | Officer | A-Award | A | Common Stock | 4,884 | 0.00 | — | 1,459,789 | D | ↗ |
| 2026-02-11 | Bancel Stephane | Director / Officer | A-Award | A | Common Stock | 11,271 | 0.00 | — | 6,193,241 | D | ↗ |
| 2026-01-05 | Mock James M | Officer | F-InKind | D | Common Stock | 780 | 30.86 | 24.1K | 43,872 | D | ↗ |
| 2025-12-11 | Bancel Stephane | Director / Officer | M-Exempt | A | Common Stock | 688,073 | 10.90 | 7.50M | 6,181,970 | D | ↗ |
| 2025-12-11 | AFEYAN NOUBAR | Director | M-Exempt | A | Common Stock | 23,853 | 10.90 | 260.0K | 27,777 | I | ↗ |
| 2025-12-09 | Hussain Abbas | Director | S-Sale | D | Common Stock | 504 | 27.60 | 13.9K | 1,515 | D | ↗ |
| 2025-12-05 | Mock James M | Officer | F-InKind | D | Common Stock | 22,817 | 25.49 | 581.6K | 43,200 | D | ↗ |
| 2025-12-05 | Klinger Shannon Thyme | Officer | M-Exempt | A | Common Stock | 47,190 | 0.00 | — | 76,048 | D | ↗ |
| 2025-12-01 | Klinger Shannon Thyme | Officer | M-Exempt | A | Common Stock | 233 | 0.00 | — | 28,971 | D | ↗ |
| 2025-12-01 | Hoge Stephen | Officer | M-Exempt | A | Common Stock | 652 | 0.00 | — | 1,455,221 | D | ↗ |
| 2025-11-28 | Mock James M | Officer | M-Exempt | D | Restricted Stock Units | 329 | 0.00 | — | 1,644 | D | ↗ |
| 2025-11-28 | Klinger Shannon Thyme | Officer | F-InKind | D | Common Stock | 160 | 25.01 | 4.0K | 28,738 | D | ↗ |
| 2025-11-28 | Hoge Stephen | Officer | F-InKind | D | Common Stock | 295 | 25.01 | 7.4K | 1,454,569 | D | ↗ |
| 2025-11-26 | Mock James M | Officer | M-Exempt | D | Restricted Stock Units | 773 | 0.00 | — | 6,963 | D | ↗ |
| 2025-11-26 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 773 | 0.00 | — | 6,963 | D | ↗ |
| 2025-11-26 | Hoge Stephen | Officer | M-Exempt | D | Restricted Stock Units | 1,437 | 0.00 | — | 12,931 | D | ↗ |
| 2025-10-03 | Mock James M | Officer | M-Exempt | A | Common Stock | 1,453 | 0.00 | — | 18,962 | D | ↗ |
| 2025-10-02 | Hussain Abbas | Director | M-Exempt | A | Common Stock | 1,439 | 0.00 | — | 2,019 | D | ↗ |
| 2025-08-29 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 232 | 0.00 | — | 466 | D | ↗ |
| 2025-08-29 | Hoge Stephen | Officer | M-Exempt | D | Restricted Stock Units | 651 | 0.00 | — | 1,304 | D | ↗ |
| 2025-08-28 | Mock James M | Officer | M-Exempt | A | Common Stock | 329 | 0.00 | — | 17,669 | D | ↗ |
| 2025-08-28 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 329 | 0.00 | — | 1,973 | D | ↗ |
| 2025-08-28 | Hoge Stephen | Officer | M-Exempt | D | Restricted Stock Units | 611 | 0.00 | — | 3,663 | D | ↗ |
| 2025-08-27 | Mock James M | Officer | F-InKind | D | Common Stock | 375 | 24.73 | 9.3K | 17,340 | D | ↗ |
| 2025-08-27 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 774 | 0.00 | — | 7,736 | D | ↗ |
| 2025-08-27 | Hoge Stephen | Officer | M-Exempt | D | Restricted Stock Units | 1,437 | 0.00 | — | 14,368 | D | ↗ |
| 2025-08-05 | Rubenstein David M. | Director | M-Exempt | A | Common Stock | 850 | 0.00 | — | 1,527 | D | ↗ |
| 2025-07-03 | Mock James M | Officer | F-InKind | D | Common Stock | 703 | 30.28 | 21.3K | 16,941 | D | ↗ |
| 2025-06-11 | Hussain Abbas | Director | S-Sale | D | Common Stock | 312 | 28.00 | 8.7K | 580 | D | ↗ |
| 2025-06-06 | Klinger Shannon Thyme | Officer | M-Exempt | A | Common Stock | 1,139 | 0.00 | — | 28,034 | D | ↗ |
| 2025-05-30 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 233 | 0.00 | — | 698 | D | ↗ |
| 2025-05-30 | Hoge Stephen | Officer | F-InKind | D | Common Stock | 316 | 26.93 | 8.5K | 1,452,119 | D | ↗ |
| 2025-05-28 | Mock James M | Officer | M-Exempt | A | Common Stock | 328 | 0.00 | — | 16,350 | D | ↗ |
| 2025-05-28 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 328 | 0.00 | — | 2,302 | D | ↗ |
| 2025-05-28 | Hoge Stephen | Officer | M-Exempt | D | Restricted Stock Units | 610 | 0.00 | — | 4,274 | D | ↗ |
| 2025-05-27 | Mock James M | Officer | M-Exempt | D | Restricted Stock Units | 773 | 0.00 | — | 8,510 | D | ↗ |
| 2025-05-27 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 773 | 0.00 | — | 8,510 | D | ↗ |
| 2025-05-27 | Hoge Stephen | Officer | M-Exempt | D | Restricted Stock Units | 1,436 | 0.00 | — | 15,805 | D | ↗ |
| 2025-04-30 | Tallett Elizabeth E | Director | A-Award | A | Stock Option (Right to Buy) | 19,134 | 28.54 | 546.1K | 19,134 | D | ↗ |
| 2025-04-30 | SAGAN PAUL | Director | A-Award | A | Stock Option (Right to Buy) | 25,512 | 28.54 | 728.1K | 25,512 | D | ↗ |
| 2025-04-30 | Rubenstein David M. | Director | M-Exempt | D | Restricted Stock Units | 677 | 0.00 | — | 0 | D | ↗ |
| 2025-04-30 | Nader Francois | Director | A-Award | A | Stock Option (Right to Buy) | 6,378 | 28.54 | 182.0K | 6,378 | D | ↗ |
| 2025-04-30 | NABEL ELIZABETH G | Director | A-Award | A | Restricted Stock Units | 16,233 | 0.00 | — | 16,233 | D | ↗ |
| 2025-04-30 | Hussain Abbas | Director | M-Exempt | D | Restricted Stock Units | 892 | 0.00 | — | 0 | D | ↗ |
| 2025-04-30 | Horning Sandra | Director | M-Exempt | D | Restricted Stock Units | 979 | 0.00 | — | 0 | D | ↗ |
| 2025-04-30 | AFEYAN NOUBAR | Director | A-Award | A | Stock Option (Right to Buy) | 25,512 | 28.54 | 728.1K | 25,512 | D | ↗ |
| 2025-04-04 | Mock James M | Officer | M-Exempt | A | Common Stock | 1,452 | 0.00 | — | 16,326 | D | ↗ |
| 2025-03-07 | Klinger Shannon Thyme | Officer | F-InKind | D | Common Stock | 551 | 34.30 | 18.9K | 25,612 | D | ↗ |
| 2025-03-03 | SAGAN PAUL | Director | P-Purchase | A | Common Stock | 31,620 | 31.76 | 1.00M | 312,027 | I | ↗ |
| 2025-03-03 | Bancel Stephane | Director / Officer | P-Purchase | A | Common Stock | 57,493 | 31.53 | 1.81M | 9,210,686 | I | ↗ |
| 2025-03-01 | Mock James M | Officer | A-Award | A | Stock Option (Right to Buy) | 63,478 | 30.96 | 1.97M | 63,478 | D | ↗ |
| 2025-03-01 | Klinger Shannon Thyme | Officer | A-Award | A | Stock Option (Right to Buy) | 55,543 | 30.96 | 1.72M | 55,543 | D | ↗ |
| 2025-03-01 | Hoge Stephen | Officer | A-Award | A | Restricted Stock Units | 148,524 | 0.00 | — | 148,524 | D | ↗ |
| 2025-03-01 | Bancel Stephane | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 357,065 | 30.96 | 11.05M | 357,065 | D | ↗ |
| 2025-02-28 | Mock James M | Officer | M-Exempt | D | Restricted Stock Units | 329 | 0.00 | — | 2,630 | D | ↗ |
| 2025-02-28 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 233 | 0.00 | — | 931 | D | ↗ |
| 2025-02-28 | Hoge Stephen | Officer | F-InKind | D | Common Stock | 296 | 31.09 | 9.2K | 1,450,727 | D | ↗ |
| 2025-02-27 | Mock James M | Officer | M-Exempt | D | Performance Stock Units | 1,326 | 0.00 | — | 0 | D | ↗ |
| 2025-02-27 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 2,653 | 0.00 | — | 0 | D | ↗ |
| 2025-02-27 | Hoge Stephen | Officer | M-Exempt | A | Common Stock | 5,746 | 0.00 | — | 1,452,855 | D | ↗ |
| 2025-02-12 | Klinger Shannon Thyme | Officer | F-InKind | D | Common Stock | 1,068 | 30.93 | 33.0K | 21,425 | D | ↗ |
| 2025-02-12 | Hoge Stephen | Officer | A-Award | A | Common Stock | 5,734 | 0.00 | — | 1,449,880 | D | ↗ |
| 2025-02-12 | Bancel Stephane | Director / Officer | F-InKind | D | Common Stock | 6,400 | 30.93 | 198.0K | 5,493,897 | D | ↗ |
| 2025-02-07 | Hoge Stephen | Officer | M-Exempt | A | Common Stock | 523 | 0.00 | — | 1,444,427 | D | ↗ |
| 2025-01-03 | Mock James M | Officer | M-Exempt | A | Common Stock | 1,453 | 0.00 | — | 12,519 | D | ↗ |
| 2024-12-09 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 529 | 44.68 | 23.6K | 20,446 | D | ↗ |
| 2024-12-06 | Klinger Shannon Thyme | Officer | M-Exempt | A | Common Stock | 1,138 | 0.00 | — | 20,975 | D | ↗ |
| 2024-12-05 | Mock James M | Officer | A-Award | A | Restricted Stock Units | 188,761 | 0.00 | — | 188,761 | D | ↗ |
| 2024-12-05 | Klinger Shannon Thyme | Officer | A-Award | A | Restricted Stock Units | 188,761 | 0.00 | — | 188,761 | D | ↗ |
| 2024-12-03 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 112 | 43.30 | 4.8K | 19,837 | D | ↗ |
| 2024-12-03 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 314 | 43.30 | 13.6K | 1,443,904 | D | ↗ |
| 2024-12-02 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 232 | 0.00 | — | 1,164 | D | ↗ |
| 2024-12-02 | Hoge Stephen | Officer | M-Exempt | A | Common Stock | 651 | 0.00 | — | 1,444,218 | D | ↗ |
| 2024-11-29 | Mock James M | Officer | S-Sale | D | Common Stock | 1,420 | 42.79 | 60.8K | 11,066 | D | ↗ |
| 2024-11-29 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 1,418 | 42.79 | 60.7K | 19,717 | D | ↗ |
| 2024-11-29 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 291 | 42.79 | 12.5K | 1,443,567 | D | ↗ |
| 2024-11-27 | Mock James M | Officer | M-Exempt | D | Restricted Stock Units | 1,326 | 0.00 | — | 1,326 | D | ↗ |
| 2024-11-27 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 2,652 | 0.00 | — | 2,653 | D | ↗ |
| 2024-11-27 | Hoge Stephen | Officer | M-Exempt | D | Restricted Stock Units | 610 | 0.00 | — | 5,495 | D | ↗ |
| 2024-11-11 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 277 | 46.10 | 12.8K | 1,443,248 | D | ↗ |
| 2024-11-08 | Hoge Stephen | Officer | M-Exempt | A | Common Stock | 523 | 0.00 | — | 1,443,525 | D | ↗ |
| 2024-10-07 | Mock James M | Officer | S-Sale | D | Common Stock | 715 | 60.12 | 43.0K | 9,505 | D | ↗ |
| 2024-10-04 | Mock James M | Officer | M-Exempt | A | Common Stock | 1,453 | 0.00 | — | 10,220 | D | ↗ |
| 2024-10-02 | Hussain Abbas | Director | A-Award | A | Stock Option (Right to Buy) | 8,093 | 63.16 | 511.2K | 8,093 | D | ↗ |
| 2024-09-09 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 551 | 73.57 | 40.5K | 18,154 | — | ↗ |
| 2024-09-06 | Klinger Shannon Thyme | Officer | M-Exempt | A | Common Stock | 1,139 | 0.00 | — | 18,705 | — | ↗ |
| 2024-09-03 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 114 | 76.99 | 8.8K | 17,566 | — | ↗ |
| 2024-09-03 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 318 | 76.99 | 24.5K | 1,443,002 | — | ↗ |
| 2024-08-30 | Klinger Shannon Thyme | Officer | M-Exempt | A | Common Stock | 233 | 0.00 | — | 17,680 | — | ↗ |
| 2024-08-30 | Hoge Stephen | Officer | M-Exempt | A | Common Stock | 652 | 0.00 | — | 1,443,320 | — | ↗ |
| 2024-08-29 | Mock James M | Officer | S-Sale | D | Common Stock | 162 | 78.03 | 12.6K | 8,767 | — | ↗ |
| 2024-08-29 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 162 | 78.03 | 12.6K | 17,447 | — | ↗ |
| 2024-08-29 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 300 | 78.03 | 23.4K | 1,442,668 | — | ↗ |
| 2024-08-28 | Mock James M | Officer | S-Sale | D | Common Stock | 1,321 | 79.39 | 104.9K | 8,600 | — | ↗ |
| 2024-08-28 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 1,319 | 79.39 | 104.7K | 17,280 | — | ↗ |
| 2024-08-28 | Hoge Stephen | Officer | M-Exempt | D | Restricted Stock Units | 611 | 0.00 | — | 6,105 | — | ↗ |
| 2024-08-27 | Mock James M | Officer | M-Exempt | A | Common Stock | 1,326 | 0.00 | — | 9,921 | — | ↗ |
| 2024-08-27 | Klinger Shannon Thyme | Officer | M-Exempt | A | Common Stock | 2,652 | 0.00 | — | 18,599 | — | ↗ |
| 2024-08-12 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 254 | 84.10 | 21.4K | 1,442,357 | — | ↗ |
| 2024-08-09 | Hoge Stephen | Officer | M-Exempt | A | Common Stock | 522 | 0.00 | — | 1,442,611 | — | ↗ |
| 2024-08-05 | Rubenstein David M. | Director | A-Award | A | Stock Option (Right to Buy) | 4,065 | 83.75 | 340.4K | 4,065 | — | ↗ |
| 2024-07-31 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 5,664 | 119.84 | 678.8K | 2,228,752 | — | ↗ |
| 2024-07-24 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 2,668 | 116.33 | 310.4K | 2,251,347 | — | ↗ |
| 2024-07-17 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 2,601 | 120.86 | 314.3K | 2,266,414 | — | ↗ |
| 2024-07-15 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 15,000 | 121.12 | 1.82M | 1,442,089 | — | ↗ |
| 2024-07-10 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 3,000 | 117.83 | 353.5K | 2,270,615 | — | ↗ |
| 2024-07-08 | Mock James M | Officer | S-Sale | D | Common Stock | 689 | 118.24 | 81.5K | 7,269 | — | ↗ |
| 2024-07-05 | Mock James M | Officer | M-Exempt | D | Restricted Stock Units | 1,452 | 0.00 | — | 13,075 | — | ↗ |
| 2024-06-26 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 1,435 | 128.78 | 184.8K | 2,289,820 | — | ↗ |
| 2024-06-18 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 1,700 | 132.22 | 224.8K | 2,312,315 | — | ↗ |
| 2024-06-17 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 15,000 | 138.16 | 2.07M | 1,457,089 | — | ↗ |
| 2024-06-14 | Bancel Stephane | Director / Officer | J-Other | A | Common Stock | 26,840 | 0.00 | — | 5,487,064 | — | ↗ |
| 2024-06-12 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 6,397 | 147.55 | 943.9K | 2,317,216 | — | ↗ |
| 2024-06-11 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 163,649 | 148.29 | 24.27M | 7,937,145 | — | ↗ |
| 2024-06-10 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 5,178 | 148.09 | 766.8K | 15,947 | — | ↗ |
| 2024-06-07 | Klinger Shannon Thyme | Officer | M-Exempt | A | Common Stock | 9,108 | 0.00 | — | 21,125 | — | ↗ |
| 2024-06-05 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 2,840 | 151.07 | 429.0K | 1,955,391 | — | ↗ |
| 2024-06-03 | Mock James M | Officer | S-Sale | D | Common Stock | 691 | 140.72 | 97.2K | 6,506 | — | ↗ |
| 2024-06-03 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 122 | 140.72 | 17.2K | 10,878 | — | ↗ |
| 2024-06-03 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 339 | 140.72 | 47.7K | 1,472,089 | — | ↗ |
| 2024-05-31 | Mock James M | Officer | M-Exempt | D | Performance Stock Units | 1,326 | 0.00 | — | 3,978 | — | ↗ |
| 2024-05-31 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 232 | 0.00 | — | 1,629 | — | ↗ |
| 2024-05-31 | Hoge Stephen | Officer | M-Exempt | D | Restricted Stock Units | 651 | 0.00 | — | 4,562 | — | ↗ |
| 2024-05-29 | Mock James M | Officer | S-Sale | D | Common Stock | 183 | 144.50 | 26.4K | 5,871 | — | ↗ |
| 2024-05-29 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 183 | 144.50 | 26.4K | 10,768 | — | ↗ |
| 2024-05-29 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 341 | 144.50 | 49.3K | 1,471,777 | — | ↗ |
| 2024-05-29 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 5,581 | 146.02 | 814.9K | 1,967,337 | — | ↗ |
| 2024-05-28 | Mock James M | Officer | M-Exempt | A | Common Stock | 328 | 0.00 | — | 6,054 | — | ↗ |
| 2024-05-28 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 1,296 | 162.47 | 210.6K | 10,623 | — | ↗ |
| 2024-05-28 | Hoge Stephen | Officer | M-Exempt | A | Common Stock | 610 | 0.00 | — | 1,472,118 | — | ↗ |
| 2024-05-24 | Mock James M | Officer | M-Exempt | A | Common Stock | 1,326 | 0.00 | — | 6,374 | — | ↗ |
| 2024-05-24 | Klinger Shannon Thyme | Officer | M-Exempt | A | Common Stock | 2,652 | 0.00 | — | 11,919 | — | ↗ |
| 2024-05-22 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 1,923 | 158.25 | 304.3K | 1,988,906 | — | ↗ |
| 2024-05-15 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 15,000 | 127.49 | 1.91M | 1,471,508 | — | ↗ |
| 2024-05-15 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 4,488 | 125.53 | 563.4K | 2,007,443 | — | ↗ |
| 2024-05-10 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 255 | 120.96 | 30.8K | 1,486,508 | — | ↗ |
| 2024-05-09 | Hoge Stephen | Officer | M-Exempt | D | Restricted Stock Units | 522 | 0.00 | — | 1,568 | — | ↗ |
| 2024-05-08 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 2,000 | 120.37 | 240.7K | 2,024,931 | — | ↗ |
| 2024-05-06 | Tallett Elizabeth E | Director | A-Award | A | Stock Option (Right to Buy) | 7,557 | 122.13 | 922.9K | 7,557 | — | ↗ |
| 2024-05-06 | SAGAN PAUL | Director | A-Award | A | Stock Option (Right to Buy) | 7,557 | 122.13 | 922.9K | 7,557 | — | ↗ |
| 2024-05-06 | Nader Francois | Director | A-Award | A | Stock Option (Right to Buy) | 7,557 | 122.13 | 922.9K | 7,557 | — | ↗ |
| 2024-05-06 | NABEL ELIZABETH G | Director | A-Award | A | Restricted Stock Units | 979 | 0.00 | — | 979 | — | ↗ |
| 2024-05-06 | LANGER ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 7,557 | 122.13 | 922.9K | 7,557 | — | ↗ |
| 2024-05-06 | Horning Sandra | Director | A-Award | A | Stock Option (Right to Buy) | 5,668 | 122.13 | 692.2K | 5,668 | — | ↗ |
| 2024-05-06 | Berenson Stephen | Director | A-Award | A | Stock Option (Right to Buy) | 7,557 | 122.13 | 922.9K | 7,557 | — | ↗ |
| 2024-05-06 | AFEYAN NOUBAR | Director | A-Award | A | Stock Option (Right to Buy) | 7,557 | 122.13 | 922.9K | 7,557 | — | ↗ |
| 2024-05-03 | NABEL ELIZABETH G | Director | M-Exempt | A | Common Stock | 732 | 0.00 | — | 2,105 | — | ↗ |
| 2024-05-03 | Berenson Stephen | Director | M-Exempt | D | Restricted Stock Units | 732 | 0.00 | — | 0 | — | ↗ |
| 2024-05-01 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 700 | 113.40 | 79.4K | 2,026,931 | — | ↗ |
| 2024-04-24 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 3,926 | 107.16 | 420.7K | 2,053,005 | — | ↗ |
| 2024-04-17 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 282 | 104.49 | 29.5K | 2,056,931 | — | ↗ |
| 2024-04-15 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 15,000 | 105.02 | 1.58M | 1,486,241 | — | ↗ |
| 2024-04-10 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 389 | 109.36 | 42.5K | 2,071,931 | — | ↗ |
| 2024-04-08 | Mock James M | Officer | S-Sale | D | Common Stock | 705 | 101.93 | 71.9K | 5,048 | — | ↗ |
| 2024-04-05 | Mock James M | Officer | M-Exempt | D | Restricted Stock Units | 1,453 | 0.00 | — | 14,527 | — | ↗ |
| 2024-04-03 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 2,702 | 103.64 | 280.0K | 2,087,031 | — | ↗ |
| 2024-03-27 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 1,817 | 105.73 | 192.1K | 2,115,114 | — | ↗ |
| 2024-03-20 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 2,113 | 101.05 | 213.5K | 2,129,818 | — | ↗ |
| 2024-03-15 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 15,000 | 103.17 | 1.55M | 1,501,241 | — | ↗ |
| 2024-03-13 | AFEYAN NOUBAR | Director | S-Sale | D | Common Stock | 412 | 109.50 | 45.1K | 2,137,338 | — | ↗ |
| 2024-03-08 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 544 | 99.05 | 53.9K | 9,267 | — | ↗ |
| 2024-03-07 | Klinger Shannon Thyme | Officer | M-Exempt | A | Common Stock | 1,138 | 0.00 | — | 9,811 | — | ↗ |
| 2024-03-04 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 117 | 94.34 | 11.0K | 8,673 | — | ↗ |
| 2024-03-04 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 309 | 94.34 | 29.2K | 1,516,241 | — | ↗ |
| 2024-03-01 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 233 | 0.00 | — | 1,861 | — | ↗ |
| 2024-03-01 | Hoge Stephen | Officer | M-Exempt | A | Common Stock | 652 | 0.00 | — | 1,516,550 | — | ↗ |
| 2024-02-29 | Mock James M | Officer | S-Sale | D | Common Stock | 647 | 94.57 | 61.2K | 4,300 | — | ↗ |
| 2024-02-29 | Klinger Shannon Thyme | Officer | S-Sale | D | Common Stock | 670 | 94.57 | 63.4K | 8,557 | — | ↗ |
| 2024-02-29 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 2,388 | 94.57 | 225.8K | 1,515,898 | — | ↗ |
| 2024-02-28 | Mock James M | Officer | M-Exempt | D | Restricted Stock Units | 1,315 | 0.00 | — | 3,945 | — | ↗ |
| 2024-02-28 | Klinger Shannon Thyme | Officer | M-Exempt | D | Restricted Stock Units | 1,315 | 0.00 | — | 3,945 | — | ↗ |
| 2024-02-28 | Hoge Stephen | Officer | M-Exempt | A | Common Stock | 2,442 | 0.00 | — | 1,518,286 | — | ↗ |
| 2024-02-27 | Mock James M | Officer | A-Award | A | Restricted Stock Units | 5,304 | 0.00 | — | 5,304 | — | ↗ |
| 2024-02-27 | Klinger Shannon Thyme | Officer | A-Award | A | Stock Option (Right to Buy) | 23,635 | 96.20 | 2.27M | 23,635 | — | ↗ |
| 2024-02-27 | Hoge Stephen | Officer | A-Award | A | Restricted Stock Units | 22,987 | 0.00 | — | 22,987 | — | ↗ |
| 2024-02-27 | Bancel Stephane | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 151,943 | 96.20 | 14.62M | 151,943 | — | ↗ |
| 2024-02-22 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 15,000 | 100.00 | 1.50M | 1,513,433 | — | ↗ |
| 2024-02-16 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 10,542 | 88.88 | 937.0K | 1,528,433 | — | ↗ |
| 2024-02-16 | Bancel Stephane | Director / Officer | S-Sale | D | Common Stock | 26,351 | 88.88 | 2.34M | 5,460,224 | — | ↗ |
| 2024-02-14 | Hoge Stephen | Officer | A-Award | A | Common Stock | 22,694 | 0.00 | — | 1,538,975 | — | ↗ |
| 2024-02-14 | Bancel Stephane | Director / Officer | A-Award | A | Common Stock | 56,736 | 0.00 | — | 5,486,575 | — | ↗ |
| 2024-02-12 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 304 | 86.23 | 26.2K | 1,516,281 | — | ↗ |
| 2024-02-09 | Hoge Stephen | Officer | M-Exempt | A | Common Stock | 522 | 0.00 | — | 1,516,585 | — | ↗ |
| 2024-01-16 | Hoge Stephen | Officer | S-Sale | D | Common Stock | 15,000 | 103.90 | 1.56M | 1,516,063 | — | ↗ |
| 2024-01-08 | Mock James M | Officer | S-Sale | D | Common Stock | 772 | 109.75 | 84.7K | 3,632 | — | ↗ |
| 2024-01-05 | Mock James M | Officer | M-Exempt | D | Restricted Stock Units | 1,452 | 0.00 | — | 15,980 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-477.2K
Shares Outstanding
396.59M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Stéphane Bancel Chief Executive Officer | 1.68M | — | 6.90M | 6.90M | 4.30M | 157.2K | 19.93M | 69.21% | ↗ |
| 2 | 2025 | Stephen Hoge, M.D. President | 1.26M | — | 9.20M | 4.60M | 2.98M | 15.8K | 18.05M | 76.41% | ↗ |
| 3 | 2025 | James Mock Chief Financial Officer | 852.2K | — | 2.45M | 1.23M | 1.31M | 15.8K | 5.86M | 62.80% | ↗ |
| 4 | 2025 | Shannon Thyme Klinger Chief Legal Officer and Corporate Secretary | 852.2K | — | 2.15M | 1.07M | 1.31M | 15.8K | 5.40M | 59.63% | ↗ |
| 5 | 2024 | Stéphane Bancel Chief Executive Officer | 1.63M | — | 7.65M | 7.65M | 1.97M | 975.2K | 19.88M | 77.02% | ↗ |
| 6 | 2024 | Shannon Thyme Klinger Chief Legal Officer and Corporate Secretary | 829.5K | — | 11.51M | 4.25M | 763.8K | 15.5K | 17.37M | 90.74% | ↗ |
| 7 | 2024 | James Mock Chief Financial Officer | 826.2K | — | 11.51M | 4.25M | 611.0K | 15.5K | 17.21M | 91.56% | ↗ |
| 8 | 2024 | Stephen Hoge, M.D. President | 1.08M | — | 4.42M | 2.21M | 1.45M | 15.5K | 9.18M | 72.25% | ↗ |
| 9 | 2023 | Stéphane Bancel Chief Executive Officer | 1.56M | — | 3.13M | 9.39M | 1.91M | 1.07M | 17.07M | 73.33% | ↗ |
| 10 | 2023 | Stephen Hoge, M.D. President | 1.04M | — | 2.71M | 2.71M | 850.5K | 22.6K | 7.34M | 73.90% | ↗ |
| 11 | 2023 | Arpa Garay Former Chief Commercial Officer | 842.3K | — | 1.46M | 1.46M | 619.7K | 63.4K | 4.45M | 65.69% | ↗ |
| 12 | 2023 | James Mock Chief Financial Officer | 792.3K | — | 1.46M | 1.46M | 583.2K | 21.1K | 4.32M | 67.65% | ↗ |
| 13 | 2023 | Shannon Thyme Klinger Chief Legal Officer and Corporate Secretary | 784.6K | — | 1.46M | 1.46M | 583.2K | 24.1K | 4.31M | 67.72% | ↗ |
| 14 | 2022 | Stéphane Bancel Chief Executive Officer | 1.42M | — | 3.60M | 10.79M | 2.70M | 851.6K | 19.36M | 74.31% | ↗ |
| 15 | 2022 | Stephen Hoge, M.D. President | 953.8K | — | 3.12M | 3.12M | 1.44M | 17.7K | 8.65M | 72.11% | ↗ |
| 16 | 2022 | Arpa Garay Chief Commercial Officer | 458.5K | 1.50M | 2.50M | 2.50M | 508.9K | 203.3K | 7.68M | 65.21% | ↗ |
| 17 | 2022 | Arpa Garay Former Chief Commercial Officer | 458.5K | 1.50M | 2.50M | 2.50M | 508.9K | 203.3K | 7.68M | 65.21% | ↗ |
| 18 | 2022 | James Mock Chief Financial Officer | 227.9K | 1.00M | 2.92M | 2.92M | 259.6K | 4.3K | 7.33M | 79.65% | ↗ |
| 19 | 2022 | Juan Andres President, Strategic Partnerships and Enterprise Expansion | 684.6K | — | 2.40M | 2.40M | 567.0K | 26.6K | 6.07M | 78.96% | ↗ |
| 20 | 2022 | David Meline Former Chief Financial Officer | 426.5K | 428.1K | 1.92M | 1.92M | — | 76.7K | 4.77M | 80.47% | ↗ |
| 21 | 2022 | Shannon Thyme Klinger Chief Legal Officer and Corporate Secretary | 692.6K | — | 1.11M | 1.11M | 756.0K | 47.2K | 3.72M | 59.80% | ↗ |
| 22 | 2022 | Jorge Gomez Former Chief Financial Officer | 5.4K | — | — | — | — | 431.7K | 437.1K | 0.00% | ↗ |
| 23 | 2021 | Stéphane Bancel Chief Executive Officer | 990.4K | — | 3.75M | 11.25M | 1.50M | 665.4K | 18.16M | 82.62% | ↗ |
| 24 | 2021 | Shannon Thyme Klinger Chief Legal Officer and Corporate Secretary | 381.1K | 250.0K | 6.00M | 4.00M | 344.0K | 514.1K | 11.49M | 87.04% | ↗ |
| 25 | 2021 | Shannon Thyme Klinger Chief Legal Officer & Corporate Secretary | 381.1K | 250.0K | 6.00M | 4.00M | 344.0K | 514.1K | 11.49M | 87.04% | ↗ |
| 26 | 2021 | Corinne Le Goff Former Chief Commercial Officer | 570.2K | 300.0K | 4.00M | 4.00M | — | 1.28M | 10.15M | 78.83% | ↗ |
| 27 | 2021 | Stephen Hoge, M.D. President | 684.8K | — | 3.00M | 3.00M | 819.0K | 299.6K | 7.80M | 76.89% | ↗ |
| 28 | 2021 | Juan Andres President, Strategic Partnerships and Enterprise Expansion | 590.8K | — | 2.50M | 2.50M | 756.0K | 256.7K | 6.60M | 75.72% | ↗ |
| 29 | 2021 | Juan Andres Chief Technical Operations & Quality Officer | 590.8K | — | 2.50M | 2.50M | 756.0K | 256.7K | 6.60M | 75.72% | ↗ |
| 30 | 2021 | David Meline Chief Financial Officer | 617.0K | — | 2.00M | 2.00M | 560.0K | 59.3K | 5.24M | 76.39% | ↗ |
| 31 | 2021 | David Meline Former Chief Financial Officer | 617.0K | — | 2.00M | 2.00M | 560.0K | 59.3K | 5.24M | 76.39% | ↗ |
| 32 | 2020 | Stéphane Bancel Chief Executive Officer | 945.7K | 1.90M | — | 9.00M | — | 1.01M | 12.89M | 69.85% | ↗ |
| 33 | 2020 | David Meline Chief Financial Officer | 334.6K | 339.3K | — | 8.60M | — | — | 9.27M | 92.73% | ↗ |
| 34 | 2020 | David Meline Former Chief Financial Officer | 334.6K | 339.3K | — | 8.60M | — | — | 9.27M | 92.73% | ↗ |
| 35 | 2020 | Stephen Hoge, M.D. President | 617.4K | 621.0K | 1.00M | 3.00M | — | 24.9K | 5.26M | 76.00% | ↗ |
| 36 | 2020 | Tal Zaks Chief Medical Office r | 548.7K | 552.0K | 750.0K | 2.25M | — | 152.3K | 4.25M | 70.54% | ↗ |
| 37 | 2020 | Juan Andres Chief Technical Operations and Quality Officer | 548.7K | 662.4K | 750.0K | 2.25M | — | 36.7K | 4.25M | 70.62% | ↗ |
| 38 | 2020 | Juan Andres President, Strategic Partnerships and Enterprise Expansion | 548.7K | 662.4K | 750.0K | 2.25M | — | 36.7K | 4.25M | 70.62% | ↗ |
| 39 | 2020 | Juan Andres Chief Technical Operations & Quality Officer | 548.7K | 662.4K | 750.0K | 2.25M | — | 36.7K | 4.25M | 70.62% | ↗ |
| 40 | 2020 | Lorence Kim, M.D. Former Chief Financial Officer | 418.2K | 145.0K | — | 2.50M | — | 330.8K | 3.39M | 73.66% | ↗ |
| 41 | 2019 | Stéphane Bancel Chief Executive Officer | 921.2K | 1.02M | — | 7.00M | — | 9.5K | 8.95M | 78.23% | ↗ |
| 42 | 2019 | Stephen Hoge, M.D. President | 595.7K | 396.0K | — | 4.00M | — | 9.5K | 5.00M | 79.98% | ↗ |
| 43 | 2019 | Tal Zaks Chief Medical Office r | 530.6K | 293.2K | — | 4.00M | — | 8.6K | 4.83M | 82.77% | ↗ |
| 44 | 2019 | Tal Zaks Chief Medical Officer | 530.6K | 293.2K | — | 4.00M | — | 8.6K | 4.83M | 82.77% | ↗ |
| 45 | 2019 | Juan Andres Chief Technical Operations & Quality Officer | 530.6K | 322.5K | — | 3.00M | — | 9.5K | 3.86M | 77.67% | ↗ |
| 46 | 2019 | Juan Andres Chief Technical Operations and Quality Officer | 530.6K | 322.5K | — | 3.00M | — | 9.5K | 3.86M | 77.67% | ↗ |
| 47 | 2019 | Lorence Kim, M.D. Chief Financial Officer | 560.4K | 278.7K | — | 2.50M | — | 258.5K | 3.60M | 69.49% | ↗ |
| 48 | 2019 | Lorence Kim, M.D. Former Chief Financial Officer | 560.4K | 278.7K | — | 2.50M | — | 258.5K | 3.60M | 69.49% | ↗ |
| 49 | 2018 | Stéphane Bancel Chief Executive Officer | 863.1K | 1.80M | — | 55.94M | — | 9.6K | 58.61M | 95.44% | ↗ |
| 50 | 2018 | John Mendlein, Ph.D., J.D. Former President, Corporate and Product Strategy | 500.0K | 400.0K | — | 25.25M | — | 8.5K | 26.16M | 96.53% | ↗ |
| 51 | 2018 | Lorence Kim, M.D. Chief Financial Officer | 542.8K | 450.5K | — | 7.82M | — | 228.4K | 9.04M | 86.48% | ↗ |
| 52 | 2018 | Lorence Kim, M.D. Former Chief Financial Officer | 542.8K | 450.5K | — | 7.82M | — | 228.4K | 9.04M | 86.48% | ↗ |
| 53 | 2018 | Stephen Hoge, M.D. President | 570.0K | 629.2K | — | 3.52M | — | 9.6K | 4.73M | 74.42% | ↗ |
| 54 | 2017 | Stephen Hoge, M.D. President | 542.3K | 4.40M | — | 19.00M | — | 9.7K | 23.95M | 79.33% | ↗ |
| 55 | 2017 | Lorence Kim, M.D. Chief Financial Officer | 521.2K | 1.00M | 5.47M | 2.16M | — | 166.6K | 9.32M | 81.88% | ↗ |
| 56 | 2017 | Stéphane Bancel Chief Executive Officer | 650.8K | 1.50M | — | 4.65M | — | 10.4K | 6.81M | 68.26% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stéphane Bancel | Chief Executive Officer & Director | 6M | male |
| Stephen Hoge | President | 4M | — |
| Shannon Thyme Klinger | Chief Legal Officer & Corporate Secretary | 2M | female |
| James Mock | Chief Financial Officer | 2M | male |
| John Lepore | Senior Vice President of Government Engagement | — | — |
| José Vega | Chief Safety Officer | — | — |
| Lavina Talukdar | Senior Vice President & Head of Investor Relations | — | female |
| Melanie Ivarsson | Chief Development Officer | — | — |
| Patrick Norman Bergstedt | Senior Vice President of Commercial Vaccines | — | male |
| Charbel Haber | Senior Vice President & Head of Global Regulatory Science | — | — |
| Tracey Franklin | Chief People & Digital Technology Officer | — | female |
| Dave Johnson | Chief Data & AI Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-08-26 | 2025-09-12 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-07-25 | 2025-08-08 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-08 | 2025-05-08 | Rob Bresnahan | PA08 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-02-25 | 2025-03-28 | Rob Bresnahan | PA08 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-01-15 | 2025-02-12 | Julie Johnson | TX32 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2024-09-09 | 2024-10-08 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2024-09-09 | 2024-10-08 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2024-03-20 | 2024-04-05 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2024-02-13 | 2024-03-06 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2024-02-01 | 2024-03-07 | Josh Gottheimer | NJ05 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2024-01-10 | 2024-02-05 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2023-11-03 | 2023-12-06 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-10-02 | 2023-11-08 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2023-09-15 | 2023-10-15 | Josh Gottheimer | NJ05 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2023-08-29 | 2023-09-06 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-08-03 | 2023-09-06 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2023-07-28 | 2023-08-07 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2023-07-12 | 2023-08-13 | Daniel Goldman | NY10 | — | Sale | $50,001 - $100,000 | ↗ |
| 2023-06-29 | 2023-07-11 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2023-05-23 | 2023-06-12 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MRNA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
